Ramipril/piretanide

Drug Profile

Ramipril/piretanide

Alternative Names: Arelix; Prilace; Trilax

Latest Information Update: 26 Aug 2004

Price : $50

At a glance

  • Originator sanofi-aventis
  • Developer Sanofi
  • Class Antihypertensives; Heterocyclic bicyclo compounds; Sulfonamides
  • Mechanism of Action ACE inhibitors; Diuretics
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Marketed Essential hypertension

Most Recent Events

  • 26 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form Sanofi-Aventis
  • 21 Jan 2000 Launched for Essential hypertension in Belgium (PO)
  • 21 Jan 2000 Launched for Essential hypertension in Germany (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top